Bevasiranib (sodium)

Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF) . It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD) .

Product Specifications

CAS Number

[849758-52-7]

UNSPSC

12352208

Target

Small Interfering RNA (siRNA) ; VEGFR

Type

Oligonucleotides

Related Pathways

Epigenetics; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/bevasiranib-sodium.html

Purity

97.68

Solubility

10 mM in H2O

Smiles

[Bevasiranib(sodium)]

Molecular Formula

C401H463N153Na40O290P40

Molecular Weight

13345.2 (free acid)

References & Citations

[1]Garba AO, Mousa SA. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010;2:75-83.|[2]Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis. 2008;14:997-1005.